Nutrient interactions and arbuscular mycorrhizas: a meta-analysis of a mycorrhiza-defective mutant and wild-type tomato genotype pair

被引:49
|
作者
Watts-Williams, Stephanie J. [1 ]
Cavagnaro, Timothy R. [2 ]
机构
[1] Monash Univ, Sch Biol Sci, Melbourne, Vic 3800, Australia
[2] Univ Adelaide, Sch Agr Food & Wine, Adelaide, SA 5064, Australia
基金
澳大利亚研究理事会;
关键词
Arbuscular mycorrhizas (AM); Micro-nutrients; Macro-nutrients; Nutrient interactions; Phosphorus (P); Zinc (Zn); 76R; rmc; Solanum lycopersicum (tomato); ZEA-MAYS L; TRIFOLIUM-SUBTERRANEUM L; PLANT-GROWTH; MINERAL-NUTRITION; BORON INTERACTION; EXTERNAL HYPHAE; HEAVY-METALS; FRUIT YIELD; SOIL ZINC; PHOSPHORUS;
D O I
10.1007/s11104-014-2140-7
中图分类号
S3 [农学(农艺学)];
学科分类号
0901 ;
摘要
Arbuscular mycorrhizas (AM) enhance plant uptake of a range of mineral nutrients from the soil. Interactions between nutrients in the soil and plant, are complex, and can be affected by AM. Using a mycorrhiza-defective mutant tomato genotype (rmc) and its wild-type (76R), provides a novel method to study AM functioning. We present a meta-analysis comparing tissue nutrient concentration (P, Zn, K, Ca, Cu, Mg, Mn, S, B, Na, Fe), biomass and mycorrhizal colonisation data between the 76R and rmc genotypes, across a number of studies that have used this pair of tomato genotypes. Particular attention is paid to interactions between soil P or soil Zn, with tissue nutrients. For most nutrients, the difference in concentration between genotypes was significantly affected either by soil P, soil Zn, or both. When soil P was deficient, AM were particularly beneficial in terms of uptake of not only P, but other nutrients as well. Colonisation by AMF significantly affects the uptake of many soil macro- and micro-nutrients. Furthermore, the soil P and Zn status also influences the difference in nutrient concentrations between mycorrhizal and non-mycorrhizal plants. The interactions identified by this meta-analysis provide a basis for future research in this area.
引用
收藏
页码:79 / 92
页数:14
相关论文
共 50 条
  • [31] Triplet chemotherapy combined with anti-EGFR treatment in RAS wild-type colon cancer: A network meta-analysis
    Di Nardo, Paola
    Giudici, Fabiola
    Basile, Debora
    De Scordilli, Marco
    Torresan, Sara
    Bortolot, Martina
    Rota, Simone
    Foltran, Luisa
    Guardascione, Michela
    Fumagalli, Arianna
    Noto, Claudia
    Guglielmi, Alessandra
    Ongaro, Elena
    Puglisi, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Risk Factors of Distant Recurrence and Dissemination of IDH Wild-Type Glioblastoma: A Single-Center Study and Meta-Analysis
    Tsuchiya, Takahiro
    Kawauchi, Daisuke
    Ohno, Makoto
    Miyakita, Yasuji
    Takahashi, Masamichi
    Yanagisawa, Shunsuke
    Osawa, Sho
    Fujita, Shohei
    Omura, Takaki
    Narita, Yoshitaka
    CANCERS, 2024, 16 (16)
  • [33] The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA)
    Basile, D.
    Pelizzari, G.
    Di Nardo, P.
    Corvaja, C.
    Ongaro, E.
    Garattini, S.
    Gerratana, L.
    Lisanti, C.
    Michele, B.
    Bortot, L.
    Buriolla, S.
    Garutti, M.
    Curtolo, G.
    Bonotto, M.
    Da Ros, L.
    Torrisi, E.
    Miolo, G.
    Cardellino, G.
    Pella, N.
    Buonadonna, A.
    Aprile, G.
    Puglisi, F.
    ANNALS OF ONCOLOGY, 2019, 30 : 79 - 79
  • [34] Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials
    Ezzeldin M. Ibrahim
    Khaled M. Abouelkhair
    Medical Oncology, 2011, 28 : 310 - 317
  • [35] Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials
    Ibrahim, Ezzeldin M.
    Abouelkhair, Khaled M.
    MEDICAL ONCOLOGY, 2011, 28 : S310 - S317
  • [36] Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
    Parikh, Aparna R.
    Gonzalez-Gugel, Elena
    Smolyakova, Natalia
    Jen, Min-Hua
    Toms, Nikki
    Lin, Yong
    Kim, Jong Seok
    Kopetz, Scott
    ONCOLOGIST, 2022, 27 (05): : 371 - 379
  • [37] Optimal Sequence and Second-Line Systemic Treatment of Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Meta-Analysis
    Wu, Chih-Chien
    Hsu, Chao-Wen
    Hsieh, Meng-Che
    Wang, Jui-Ho
    Chang, Min-Chi
    Yang, Ching-Shiang
    Su, Yi-Chia
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [38] Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis
    Jiang, Wei
    Yu, Qitao
    Ning, Ruiling
    Zhao, Wenhua
    Wei, Changyuan
    ONCOTARGETS AND THERAPY, 2018, 11 : 4271 - 4281
  • [39] Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA)
    Di Nardo, P.
    Basile, D.
    Siciliano, A.
    Pelizzari, G.
    Corvaja, C.
    Buriolla, S.
    Ongaro, E.
    Grazia, D. Maria
    Garattini, S. K.
    Foltran, L.
    Guardascione, M.
    Casagrande, M.
    Buonadonna, A.
    Prantera, T.
    Aprile, G.
    Puglisi, F.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (05) : 786 - 794
  • [40] The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis
    Ciliberto, Domenico
    Staropoli, Nicoletta
    Caglioti, Francesca
    Chiellino, Silvia
    Ierardi, Antonella
    Ingargiola, Rossana
    Botta, Cirino
    Arbitrio, Mariamena
    Correale, Pierpaolo
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 69 - 77